US 10035822
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
granted A61KA61K38/00A61K38/005
Quick answer
US patent 10035822 (Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods) held by Apellis Pharmaceuticals, Inc. expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Apellis Pharmaceuticals, Inc.
- Grant date
- Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K38/00, A61K38/005, A61K38/10, A61K47/542